newsfilter
← Latest News
GlobeNewswire·

Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights

Third quarter TONMYA® net sales of approximately $15 million, up 37% from the second quarter Approximately $163 million in cash and cash equivalents as of September 30, 2026 Strategic focus on supporting TONMYA growth